Difference between revisions of "FOXD3-AS1"
Jiabao Cao (talk | contribs) |
|||
Line 1: | Line 1: | ||
+ | |||
==Annotated Information== | ==Annotated Information== | ||
− | === | + | ===Name=== |
− | FOXD3-AS1 | + | FOXD3-AS1:FOXD3 antisense RNA 1 (head to head) |
− | + | ||
− | FOXD3 antisense RNA 1 (head to head) | ||
− | |||
− | |||
− | |||
pasFOXD3 | pasFOXD3 | ||
− | === | + | ===Characteristics=== |
− | + | FOXD3-AS1 is the antisense transcript of a protein coding gene FOXD3. In addition, transcript factors chip-seq data from encode/analysis (http://genome.ucsc.edu/) show that FOXD3-AS1 shares its mRNA partner FOXD3 the promoter region, meaning that FOXD3-AS1 belongs to a category of lncRNA called promoter upstream transcripts (PROMPTs).<ref name="ref1" /> | |
− | === | + | |
− | + | ===Function=== | |
− | === | + | [[ |
− | + | FOXD3-AS1 knockdown significantly inhibits cell proliferation, induces cell cycle S-phase arrest, and impaires cell migration and invasion in malignant glioma cells. As expected, The expression of FOXD3-AS1 is positively correlated with FOXD3 mRNA. Knockdown of FOXD3-AS1 reduces the protein level of FOXD3 in cultured U251 and A172 cell lines.<ref name="ref1" /> | |
− | === | + | |
− | + | ===Expression=== | |
− | === | + | |
− | + | The expression of FOXD3-AS1 is significantly higher in the high-grade glioma tissues compared with that in the normal brain tissues and low-grade glioma tissues (both P<0.01). And patients with low FOXD3-AS1 expression had grater survival probability.<ref name="ref1" /> | |
− | === | + | ===Diseases=== |
− | glioma | + | Glioma<ref name="ref1" /> |
+ | ===Sequence=== | ||
+ | >NR_121634.1 Homo sapiens FOXD3 antisense RNA 1 (head to head) (FOXD3-AS1), transcript variant 1, long non-coding RNA | ||
+ | <dnaseq>AGGGAATTGTCAACAAAGGGACGAGAGACGCGCAACTCCGCTCCGCACTGTGCGCCAGCATCCCCGGGGC | ||
+ | ACGGAGGGCGCTGCGGCCCGCCCGGAGACCCCCCCACCCAGGCTGGATCCGGGCCCTGGGGCCCAGGGAG | ||
+ | CGGCTTTAAAGAGTAAGAGCAGCGCACCCGGCTCCCTCCTGCTAATTAGATTTCAGATTCCCCTCTGGCC | ||
+ | TCAGTGCTCATTCCGGGGAAGACACCTGCTGAGATGTCTTTTTCCCCCTCCCCCAACCAAACCACTCAGG | ||
+ | TCCTACCTGCTCTTTCCCGGCTTGATGCGGGCGTGTTTTCCTGTATGTATTTTTTCGTGCGGCCACAAAA | ||
+ | AGCATCAGCTGGGGTTCCCGAAGGTCAGAAAATGGCTATTGATTAATCTACTAGAATAGTTGCCGAGAGA | ||
+ | AATAAAAACGACGTAAAATAGCAGGGAACCTATAAATAAAGAAGCCATAACTGGCTACTTGGAGTTGTTA | ||
+ | AACGACTTAGCATATGAAAAAATCGGAAATGAGGCGCTGGGGAAGGAGCTGGGATTGGCAGCGGCCTGGG | ||
+ | TGTGGACAAATCCTCCAAGATTTAACTTCCAAGAAAACCGGCGGCGGAGCGGGTGGAGGAGGCGAGGATG | ||
+ | TGTGGCCAATGCACGCGGAGTGCAAGGCCGCCTAGTTGGGAGCCGCAAGAGCCTGCCTGGTGTGGCAGGC | ||
+ | ACACGGAACCCAATCCCTGTCTGTCCGCTGCGGCCTGGGAGGGGAGCGCCGGCCTCACCAGAGGAAGGAG | ||
+ | CACGAGGGGAGGAGTTCCGAGAGGAAATAATTAGTGAAATATTTGCAGAAGATGCTGGGATGTGGATTTA | ||
+ | ATTCCGGATGGACAGTGGTGCTTCTGATTCCCTCAGTCTGTTTCCCCACCCACGATCTCCTCTTTCCTTG | ||
+ | GCCTAGACACACCAAAAATAATTCAATAAAATAAAAATAAAAATTTAAAAATC</dnaseq> | ||
+ | ==Labs working on this lncRNA== | ||
+ | *Department of Neurosurgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China; Department of Neurosurgery, The First People's Hospital of Nantong, Medical School of Nantong UniversityJiangsu Province, China. | ||
+ | ==References== | ||
+ | <references> | ||
+ | <ref name="ref1"> | ||
+ | Chen ZH, Hu HK, Zhang CR, Lu CY, Bao Y, Cai Z, Zou YX, Hu GH, Jiang L. | ||
+ | Down-regulation of long non-coding RNA FOXD3 antisense RNA 1 (FOXD3-AS1) inhibits | ||
+ | cell proliferation, migration, and invasion in malignant glioma cells. Am J | ||
+ | Transl Res. 2016 Oct 15;8(10):4106-4119. | ||
+ | </ref> | ||
+ | </references> |
Revision as of 11:20, 10 November 2017
Contents
Annotated Information
Name
FOXD3-AS1:FOXD3 antisense RNA 1 (head to head)
pasFOXD3
Characteristics
FOXD3-AS1 is the antisense transcript of a protein coding gene FOXD3. In addition, transcript factors chip-seq data from encode/analysis (http://genome.ucsc.edu/) show that FOXD3-AS1 shares its mRNA partner FOXD3 the promoter region, meaning that FOXD3-AS1 belongs to a category of lncRNA called promoter upstream transcripts (PROMPTs).[1]
Function
[[ FOXD3-AS1 knockdown significantly inhibits cell proliferation, induces cell cycle S-phase arrest, and impaires cell migration and invasion in malignant glioma cells. As expected, The expression of FOXD3-AS1 is positively correlated with FOXD3 mRNA. Knockdown of FOXD3-AS1 reduces the protein level of FOXD3 in cultured U251 and A172 cell lines.[1]
Expression
The expression of FOXD3-AS1 is significantly higher in the high-grade glioma tissues compared with that in the normal brain tissues and low-grade glioma tissues (both P<0.01). And patients with low FOXD3-AS1 expression had grater survival probability.[1]
Diseases
Glioma[1]
Sequence
>NR_121634.1 Homo sapiens FOXD3 antisense RNA 1 (head to head) (FOXD3-AS1), transcript variant 1, long non-coding RNA
000081 CTGCGGCCCG CCCGGAGACC CCCCCACCCA GGCTGGATCC GGGCCCTGGG GCCCAGGGAG CGGCTTTAAA GAGTAAGAGC 000160
000161 AGCGCACCCG GCTCCCTCCT GCTAATTAGA TTTCAGATTC CCCTCTGGCC TCAGTGCTCA TTCCGGGGAA GACACCTGCT 000240
000241 GAGATGTCTT TTTCCCCCTC CCCCAACCAA ACCACTCAGG TCCTACCTGC TCTTTCCCGG CTTGATGCGG GCGTGTTTTC 000320
000321 CTGTATGTAT TTTTTCGTGC GGCCACAAAA AGCATCAGCT GGGGTTCCCG AAGGTCAGAA AATGGCTATT GATTAATCTA 000400
000401 CTAGAATAGT TGCCGAGAGA AATAAAAACG ACGTAAAATA GCAGGGAACC TATAAATAAA GAAGCCATAA CTGGCTACTT 000480
000481 GGAGTTGTTA AACGACTTAG CATATGAAAA AATCGGAAAT GAGGCGCTGG GGAAGGAGCT GGGATTGGCA GCGGCCTGGG 000560
000561 TGTGGACAAA TCCTCCAAGA TTTAACTTCC AAGAAAACCG GCGGCGGAGC GGGTGGAGGA GGCGAGGATG TGTGGCCAAT 000640
000641 GCACGCGGAG TGCAAGGCCG CCTAGTTGGG AGCCGCAAGA GCCTGCCTGG TGTGGCAGGC ACACGGAACC CAATCCCTGT 000720
000721 CTGTCCGCTG CGGCCTGGGA GGGGAGCGCC GGCCTCACCA GAGGAAGGAG CACGAGGGGA GGAGTTCCGA GAGGAAATAA 000800
000801 TTAGTGAAAT ATTTGCAGAA GATGCTGGGA TGTGGATTTA ATTCCGGATG GACAGTGGTG CTTCTGATTC CCTCAGTCTG 000880
000881 TTTCCCCACC CACGATCTCC TCTTTCCTTG GCCTAGACAC ACCAAAAATA ATTCAATAAA ATAAAAATAA AAATTTAAAA 000960
000961 ATC
Labs working on this lncRNA
- Department of Neurosurgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China; Department of Neurosurgery, The First People's Hospital of Nantong, Medical School of Nantong UniversityJiangsu Province, China.